Molecule action mechanisms of NM-3 on human gastric cancer SGC-7901 cells in vivo or in vitro

Table 1 Growth of neo-microvascular around gastric tumor supressed by NM-3 (x^-±s)

Treatment	n	Density (mm3)
Carboplatin	10	4.72 ± 1.18a
NM-3 plus carboplatin	10	1.18 ± 0.05b
Saline	10	5.37 ± 1.72

^aP > 0.05,

^bP < 0.01 vs t test in saline control group.

Table 2 Apoptotic indix (AI) of human gastric cancer line SGC-7901 enhanced by NM-3 in vitro (x^-±s)

Treatment	n	AI (TUNEL)%	AI (FACScan)%
NM-3	10	16.47 ± 4.13b	15.97 ± 2.49b
Carboplatin	10	12.94 ± 2.12b	11.86 ± 1.09b
NM-3 plus carboplatin	10	27.98 ± 6.12b	26.86 ± 5.69b
Saline	10	1.83 ± 0.12	1.06 ± 0.09

^aP > 0.05,

^bP < 0.01 vs t test, in saline control group.

Table 3 Growth of xerografted human gastric tumor affected by NM-3 in nude mice (x^-±s)

Treatment	n	Weight (g)	Size (cm3)
NM-3	10	4.17 ± 0.22a	0.68 ± 0.07a
Carboplatin	10	4.46 ± 0.23a	0.71 ± 0.08a
NM-3 plus carboplatin	10	2.78 ± 0.18b	0.34 ± 0.02b
Saline	10	9.45 ± 1.38	8.94 ± 1.46

^aP < 0.05,

^bP < 0.01 vs t test, in saline control group.